Nicotinic cholinergic receptors undergo desensitization upon repeated or prolonged exposure to agonist. We investigated the effects of a novel chromogranin A catecholamine release-inhibitory fragment, catestatin (chromogranin A 344 -364 ), on agonist-induced desensitization of catecholamine release from pheochromocytoma cells. In a dose-dependent fashion, the nicotinic antagonist catestatin blocked agonist desensitization of both catecholamine release (IC 50 Nicotinic cholinergic receptors are extracellular ligand-gated pentameric cation channels activated by the endogenous neurotransmitter acetylcholine or its exogenous analogs such as nicotine (1, 2). The nicotinic family consists of several distinct but related receptor subtypes. 10 different nicotinic acetylcholine receptor subunits (␣2-␣8 and 2-4) have been identified in vertebrate neurons (2, 3), and PC12 pheochromocytoma cells express ␣3, ␣5, ␣7, 2, and 4 nicotinic subunits (4, 5).Desensitization (sometimes referred to tolerance, refractoriness, subsensitivity, or down-regulation) denotes loss of cell or tissue responses after repeated or prolonged application of a stimulus. Nicotinic receptor desensitization by agonist has been known for at least 40 years, since Katz and Thesleff (6) first characterized the phenomenon at the neuromuscular junction. Nicotinic desensitization occurs at both muscle-type and neuronal-type nicotinic receptors (7,8). Desensitization takes place in cell lines that express nicotinic functions, such as nicotine-induced release of norepinephrine from adrenal chromaffin cells (9), or agonist-induced Na ϩ (10, 11) or other cation (12) fluxes in PC12 pheochromocytoma cells. Cell lines transfected with defined subunits of nicotinic receptors (such as ␣2-2 (13) or ␣4-2 (14)) also desensitize upon exposure to agonist. Recently, nicotinic receptor desensitization has been shown to occur in midbrain dopamine neurons (15).Desensitization of the nicotinic acetylcholine receptor may be modulated by a variety of factors. Noncovalent modulators include the noncompetitive nicotinic blockers (7), calcium (7), the thymic peptide hormones thymopoietin and thymopentin (7), substance P (9), and calcitonin gene-related peptide (7). Covalent modifications of receptor structure, such as receptor phosphorylation (16), may also play a role.The neuropeptide substance P modifies the nicotinic response of chromaffin cells by two distinct actions: (i) substance P inhibits the secretion of catecholamines evoked by nicotinic agonists (17), and (ii) substance P protects against desensitization of this nicotinic response (17). These effects of substance P are selective for the nicotinic receptor ionophore complex, rather than tachykinin receptors (18).The catestatin peptide fragment of the catecholamine secretory vesicle protein chromogranin A (bovine chromogranin A 344 -364 ) is a potent inhibitor of exocytotic catecholamine secretion from PC12 and chromaffin cells (19,20). This peptide acts as a noncompetitive nicotinic cholinergic antagonist, with ch...